Infant Jaundice

Neonatal jaundice (hyperbilirubinemia) is the yellow discoloration of a newborn's skin and eyes caused by an elevated level of unconjugated (indirect) bilirubin, and it is genuinely common: visible jaundice affects a large majority of term newborns, and an even higher share of preterm infants, at some point in the first week of life, with roughly 10% of term and preterm newborns going on to develop a total serum bilirubin (TSB) level that is clinically significant enough to require treatment.^[1]

The elevated bilirubin reflects two things happening at once in every newborn. Red blood cell mass is higher and red cell lifespan shorter than in an adult, so more bilirubin is produced from heme breakdown; at the same time, the hepatic conjugating enzyme UGT1A1 is developmentally immature at birth — its activity is estimated at only about 1% of adult levels — so the liver cannot yet clear bilirubin as fast as it is being produced. Increased enterohepatic recirculation, where unconjugated bilirubin in the gut is reabsorbed back into the bloodstream rather than excreted in stool, adds a third contributing factor.^[2]

This chapter's underlying urgency is set by a single fact: the entire reason any of this matters is preventing bilirubin from ever reaching a neurotoxic level. Severe, untreated hyperbilirubinemia can cause acute bilirubin encephalopathy and, if it progresses, permanent kernicterus — a largely preventable but genuinely devastating outcome that can leave a child with choreoathetoid cerebral palsy, an upward-gaze abnormality, dental enamel hypoplasia of the primary teeth, and sensorineural hearing loss.^[2][1] The encouraging counterpart to that risk is that neonatal jaundice is also one of the most predictable, most measurable, and most treatable conditions in this library: a validated, hour-specific threshold tells clinicians exactly when to act, and phototherapy — safe, non-invasive, and effective — resolves the overwhelming majority of cases well before a dangerous level is ever reached.

Physiologic jaundice — the most common presentation

In a well term infant, physiologic jaundice reflects the normal bilirubin-handling limitations described in the Overview rather than any underlying disease. It characteristically appears after the first 24 hours of life, rises to a peak around 48-96 hours of age (Canadian data describe a slightly later population peak of roughly 72-120 hours, by which point many infants are already home), and resolves on its own, typically within about 2-3 weeks.^[2][1] No treatment beyond routine monitoring and feeding support is needed for genuinely physiologic jaundice, and this pattern accounts for the great majority of newborn jaundice a pharmacist will be asked about.

Pathologic jaundice — always concerning, defined mainly by timing

Pathologic jaundice is distinguished less by a single bilirubin number than by when and how fast it happens. Three features should immediately raise concern:

• Onset within the first 24 hours of life — the single most important, most testable red-flag distinction in this entire chapter; current Canadian guidance lists it explicitly as a hyperbilirubinemia risk factor that warrants investigation rather than routine reassurance.^[1]
• A rapid rate of rise — a TSB increasing by 5 µmol/L per hour or more within the first 24 hours of life, or by 3.5 µmol/L per hour or more beyond 24 hours, is treated as evidence of hemolysis and needs urgent evaluation rather than routine follow-up.^[1]
• An unusually high peak for the infant's precise age in hours and gestational age, plotted against the validated threshold graphs described in Assessment/Diagnosis — not against a single fixed number that applies to every baby.

Jaundice persisting beyond about 2 weeks in a term infant (or 3 weeks in an exclusively breastfed infant) is termed prolonged jaundice and needs its own dedicated workup rather than continued reassurance — see Assessment/Diagnosis and Monitoring/Follow-up.

Breastfeeding jaundice vs. breast-milk jaundice — two genuinely different entities

These two are frequently confused by parents, and sometimes by clinicians, but they have different mechanisms, different timing, and different — though equally reassuring — counselling messages. Neither is, on its own, a reason to stop breastfeeding.^[3]

^[3] As a rough numeric anchor cited in this literature: a bilirubin below about 12 mg/dL (roughly 205 µmol/L), or between 12-20 mg/dL (roughly 205-340 µmol/L) with no evidence of hemolysis, is managed with continued breastfeeding; only above about 20 mg/dL (roughly 340 µmol/L) is a brief 24-hour interruption even considered, and this remains an individualized, specialist-guided decision rather than a routine step.^[3]

Cephalohematoma and significant bruising

Extravasated blood from a birth-related cephalohematoma or significant bruising is broken down and adds an additional bilirubin load as it resorbs, which can prolong or worsen jaundice over the following 1-2 weeks in an otherwise well infant — a genuinely common, easily explained cause worth specifically asking about.^[1]

Hyperbilirubinemia risk factors

• Lower gestational age (under 38 weeks) — prematurity is one of the single largest risk factors for more severe hyperbilirubinemia, both because hepatic conjugation is even less mature and because a preterm infant tolerates a given bilirubin level less safely.^[1]
• Jaundice appearing in the first 24 hours of life.^[1]
• Evidence of hemolysis: a positive direct antiglobulin (Coombs) test, an abnormal blood smear, or an elevated hemoglobin/hematocrit.^[1]
• Need for phototherapy already in the first 72 hours of life.^[1]
• A family history of a sibling who needed treatment for hyperbilirubinemia.^[1]
• A genetic predisposition to red cell disorders, including G6PD deficiency (see below).^[1]
• Suboptimal oral feeding or excessive weight loss (roughly over 10% of birth weight).^[1]
• Significant bruising or a cephalohematoma.^[1]
• Polycythemia.^[1]

Neurotoxicity risk factors — a separate, equally important list

These factors do not necessarily raise the bilirubin level itself, but they lower the level at which a given TSB becomes dangerous, which is why they shift treatment thresholds downward (see Choose Initial Treatment):

• Lower gestational age (under 38 weeks).^[1]
• Hypoalbuminemia (serum albumin under 30 g/L) — less albumin-bound capacity means more free bilirubin able to cross into brain tissue.^[1]
• A suspected or diagnosed hemolytic condition.^[1]
• Suspected or culture-proven sepsis.^[1]
• Hemodynamic or respiratory instability in the preceding 24 hours.^[1]

ABO/Rh incompatibility

A mismatch between maternal and fetal/neonatal blood groups — most importantly Rh(D) alloimmunization, and ABO incompatibility such as a group O mother with a group A or B infant — allows maternal antibodies that crossed the placenta to hemolyze fetal and neonatal red cells, producing a bilirubin load well above the ordinary physiologic amount. Universal prenatal maternal blood-group and antibody screening is recommended, but universal newborn direct antiglobulin testing (DAT) is not, since a positive DAT does not reliably predict clinically significant hemolysis and does not by itself measure how strong the hemolysis actually is.^[1]

G6PD deficiency

G6PD deficiency is now recognized as a leading cause of kernicterus arising from severe neonatal hyperbilirubinemia, accounting for an estimated 1 in 5 kernicterus cases in some analyses.^[1][4] Consider it specifically in an infant with jaundice that is persistent, unresponsive to phototherapy, or occurring without any other apparent risk factor — particularly where family background carries a higher G6PD-deficiency prevalence. An important testing caveat: active hemolysis can produce a falsely normal (negative) G6PD result, so a normal test obtained during an acute hemolytic episode should be repeated around 3 months of age to confirm it.^[1] Universal newborn G6PD screening is not currently recommended, largely because results do not return quickly enough to inform acute management; the practical substitute is universal caregiver education about avoiding known hemolytic triggers.^[4]

Prematurity, including "late preterm" infants

Even infants born at 35-37 weeks — who are frequently handled clinically as though they were full term — carry a meaningfully higher risk of more severe hyperbilirubinemia and are followed and treated using their own, lower gestational-age-specific phototherapy and exchange-transfusion thresholds, not term thresholds.^[1]

Diagnosis is a measurement, not a look

Visual assessment of an infant's skin colour is a genuinely unreliable way to estimate how high a bilirubin level actually is — an important point to actively correct, since informally "eyeballing" jaundice severity remains common practice. This is especially true in infants with darker skin tones, where visible yellowing is harder to appreciate at any given bilirubin level.^[1] The complete absence of any visible jaundice in the first 48 hours of life is reasonably reassuring against significant disease, but its presence, at any visible degree, should prompt an actual transcutaneous or serum bilirubin measurement rather than an estimate of severity by eye.^[1]

Measuring bilirubin

Total serum bilirubin (TSB), drawn by venous or capillary sample, and transcutaneous bilirubin (TcB), measured non-invasively with a handheld meter, are both acceptable. TcB is a reasonable screening estimate when the reading is below about 250 µmol/L; if a TcB result comes back within about 50 µmol/L of the phototherapy threshold, it should be confirmed with an actual TSB draw before a treatment decision is made.^[1] A first bilirubin check is generally obtained no earlier than 12 hours after birth, and can reasonably be timed to coincide with routine newborn metabolic screening.^[1]

Plotting the result against a validated, hour-specific threshold

A single bilirubin number means little on its own — what matters is that number plotted against the infant's precise age in hours and gestational age, since a level that is entirely unremarkable at 96 hours of age would be a genuine emergency at 24 hours. This is the core logic behind the hour-specific bilirubin nomogram approach long used across North America (the Bhutani nomogram and its descendants), which sorts infants into low-, intermediate-, and high-risk zones based on percentile tracks. Current Canadian guidance builds on this same hour-specific logic but frames the decision using separate gestational-age-specific phototherapy and exchange-transfusion threshold graphs — stratified further by whether any neurotoxicity risk factor from Risk Factors is present — together with a "delta" calculation (ΔTSB or ΔTcB): the gap between the measured value and the age-specific phototherapy threshold. This delta value has been shown to better predict which infants will actually go on to need treatment than the original nomogram-percentile approach alone, and it is what drives both the treatment decision and the follow-up interval (see Choose Initial Treatment and Monitoring/Follow-up).^[1]

Additional workup — when and what

For an infant with a hemolysis risk factor (see Risk Factors) or a bilirubin level requiring treatment, obtain a direct antiglobulin (Coombs) test, blood group and Rh type for both infant and mother, hemoglobin/hematocrit, and reticulocyte count.^[1] For prolonged jaundice — beyond about 2 weeks in a term infant, or 3 weeks in an exclusively breastfed infant — investigate for urinary tract infection, thyroid disease, ongoing hemolytic disease, and inborn errors of metabolism, and measure the direct (conjugated) bilirubin fraction specifically: a result above 17 µmol/L is abnormal and should prompt urgent evaluation for cholestasis (for example, biliary atresia) rather than being attributed to ordinary prolonged physiologic or breast-milk jaundice.^[1]

Differential diagnosis

^[1][3]

• Prevent TSB from ever reaching the neurotoxic levels that risk acute bilirubin encephalopathy and, ultimately, kernicterus — the framing that drives every other goal in this chapter.
• Recognize the single most testable red flag — jaundice within the first 24 hours of life — and act on it the same day rather than deferring to a routine visit.
• Identify infants with an underlying hemolytic process (ABO/Rh incompatibility, G6PD deficiency) early, since these infants both rise faster and tolerate a given bilirubin level less safely.
• Use a measured, hour-specific bilirubin value plotted against a validated threshold — never a visual estimate — to make every treatment decision.
• Deliver phototherapy effectively when indicated, and recognize when a case has crossed from a phototherapy-level problem into an exchange-transfusion-level emergency.
• Support effective, frequent breastfeeding as first-line management for feeding-related jaundice, rather than recommending it be stopped.
• Ensure every family discharged before bilirubin typically peaks (roughly 72-120 hours of age) has a clear, appropriately timed follow-up plan and knows exactly what to watch for at home.
• Correct two persistent misconceptions: that jaundice severity can be reliably judged by looking at the baby, and that breast-milk jaundice means breastfeeding has to stop.

Phototherapy in practice — what effective delivery looks like

A newborn undergoing conventional overhead phototherapy for neonatal jaundice — eyes are shielded, the diaper is left on, and the rest of the skin is exposed to maximize the treated surface area. (Martin Pot, CC BY 3.0, Wikimedia Commons)

Maximize the skin surface area exposed to the light: undress the infant to a diaper, shield the eyes, and reposition periodically so different areas of skin are exposed over the course of treatment.^[1] A fiberoptic phototherapy blanket, wrapped directly against the skin, is a genuinely useful option because it allows continued holding and feeding during treatment without interrupting light exposure, and is sometimes combined with an overhead unit for "double phototherapy" in a more severe case.^[1] For infants with only mild hyperbilirubinemia, brief interruptions of the light — roughly 20-30 minutes, 8-10 times a day — for breastfeeding, skin-to-skin contact, and diaper changes are acceptable and do not meaningfully reduce effectiveness; this is worth stating explicitly to parents, since interrupting rare, precious early bonding and feeding time is a common practical worry.^[1]

Feeding support — the central non-drug intervention

For breastfeeding (suboptimal-intake) jaundice specifically, the actual treatment is improving breastfeeding, not stopping it. This means: assessing and correcting latch and positioning, increasing feeding frequency (typically at least 8-12 times in 24 hours for a healthy term newborn), waking a sleepy infant for feeds rather than letting a long stretch pass, confirming adequate transfer through audible swallowing and appropriate wet/soiled diaper counts, and arranging prompt lactation support when feeding is not yet well established.^[1][5] Frequent, effective feeding works by increasing stool output, which reduces the enterohepatic recirculation of bilirubin back into the bloodstream and gives the immature newborn liver less to reprocess.^[5] Short-term formula supplementation is occasionally used for a genuinely dehydrated or significantly underfed infant, but the routine, reflexive response to jaundice in a breastfed infant should be to fix breastfeeding, not to abandon it.

What NOT to do

Do not routinely advise stopping breastfeeding for either breastfeeding jaundice or breast-milk jaundice. For breastfeeding jaundice specifically, stopping removes the actual fix — more effective, more frequent feeding. For breast-milk jaundice, a brief interruption is, at most, a diagnostic step reserved for an unusually high or refractory bilirubin level under specialist direction, not a routine recommendation.^[3] Do not recommend sunlight exposure through a window as a substitute for clinical phototherapy — window glass filters out the effective wavelengths, and unshielded direct sun exposure risks sunburn; this is a genuine, still-circulating piece of outdated home advice worth proactively correcting.

Premature and "late preterm" infants (35-37 weeks)

Even late-preterm infants, though sometimes managed clinically as though they were full term, have their own lower gestational-age-specific phototherapy and exchange-transfusion thresholds and a higher risk of more severe hyperbilirubinemia and its complications. Use the correct gestational-age-specific threshold graph rather than a generic one.^[1]

Infants with a hemolytic condition (ABO/Rh incompatibility, G6PD deficiency)

This group rises faster, tolerates a given bilirubin level less safely (a "neurotoxicity risk factor" per Canadian guidance), and is followed and treated using lower thresholds and shorter monitoring intervals — recheck TSB within 6-12 hours and every 24 hours after stopping phototherapy until a clear downward trend is confirmed.^[1]

Exclusively breastfed infants

As a group, breastfed infants carry a higher risk of clinically significant hyperbilirubinemia than formula-fed infants, almost always related to feeding volume/frequency rather than any inherent problem with breast milk itself. The response is feeding support, not formula substitution or stopping breastfeeding — the benefits of breastfeeding meaningfully outweigh this small, manageable risk.^[1]

Infants discharged early (before 72 hours of age)

Since peak bilirubin typically occurs between about 72 and 120 hours of age — after most healthy newborns are already home — this is one of the most practically important populations in the entire chapter. A clear, risk-appropriate follow-up plan made before discharge is not optional extra care; it is the primary safety net for the majority of clinically significant hyperbilirubinemia. See Monitoring/Follow-up for specific interval guidance.^[1]

Infants who reached a high peak bilirubin or required exchange transfusion

Refer for audiology assessment if peak TSB exceeded 400 µmol/L, or if the pre-exchange-transfusion threshold was reached or exceeded, or if the infant received an exchange transfusion — hearing risk rises significantly across the range of roughly 400-600 µmol/L.^[1] Refer for neurodevelopmental follow-up under the same reached/exceeded-pre-exchange-threshold criteria, with or without an actual exchange transfusion, or if abnormal neurological signs were present.^[1] For an infant with immune hemolytic disease, watch specifically for late anemia — check hemoglobin at 4-6 weeks if no exchange transfusion was needed, or 8-10 weeks if one was performed.^[1]

• Assign every newborn a follow-up bilirubin-check interval based on their measured value's position relative to the risk zone/threshold (the delta calculation) at the time of discharge — not a single fixed number of days applied to every baby.^[1]
• For a higher-risk hemolytic infant on or recently off phototherapy, recheck within 6-12 hours and every 24 hours thereafter until a clear downward trend is confirmed.^[1]
• After stopping phototherapy for a lower-risk infant, recheck TSB 12-24 hours later to rule out clinically significant rebound.^[1]
• Counsel every family, before discharge, on the expected pattern: jaundice typically starts on the face, spreads toward the trunk and then the limbs as the level rises, and peaks around days 3-5 of age — often after the family is already home. Give a specific, written follow-up appointment rather than a vague "come back if you're worried."^[5]
• For jaundice persisting beyond about 2 weeks (3 weeks if exclusively breastfed), arrange the prolonged-jaundice workup described in Assessment/Diagnosis rather than continued reassurance.^[3]
• Refer for audiology and/or neurodevelopmental follow-up per the criteria in Special Populations for any infant who reached a high peak level or needed exchange transfusion.^[1]
• Reinforce return precautions at every contact: refusal to feed, extreme sleepiness, more than about 10% birth-weight loss, jaundice spreading to the arms or legs, or any sign of acute bilirubin encephalopathy.^[5][1]

1. TSB continues rising despite intensive phototherapy, approaching the pre-exchange-transfusion threshold (the "fourth rule of 30"): escalate immediately — intensify phototherapy (confirm irradiance and skin exposure, add a second unit for double phototherapy), draw urgent labs, alert the blood bank, withhold feeds, start IV fluids, and consult neonatology without delay.^[1]
2. Isoimmune hemolytic disease with TSB at the pre-exchange threshold and exchange transfusion cannot be arranged promptly: consider IVIG 0.5-1 g/kg IV over 2 hours as a bridge, understanding that the evidence for benefit is genuinely mixed.^[1]
3. TSB reaches the exchange-transfusion threshold, or any sign of acute bilirubin encephalopathy appears at any bilirubin level: exchange transfusion in a capable NICU is the emergency next step — do not continue trialing phototherapy alone.^[1]
4. Jaundice persists beyond the expected window (2 weeks in a term infant, 3 weeks if exclusively breastfed), or the direct/conjugated bilirubin fraction is elevated (over 17 µmol/L): pursue the prolonged-jaundice/cholestasis workup rather than assuming ongoing breast-milk jaundice.^[1]
5. A family struggling with breastfeeding frequency or effectiveness despite counselling, or genuine uncertainty about follow-up timing: arrange dedicated, hands-on lactation support and confirm the next bilirubin-check appointment before the visit ends, rather than assuming the initial counselling was sufficient.

• Estimating bilirubin severity by looking at the baby rather than measuring it — genuinely unreliable, especially in darker-skinned infants.^[1]
• Treating jaundice appearing within the first 24 hours of life as routine or physiologic rather than urgent.^[1]
• Recommending that breastfeeding be stopped for breastfeeding jaundice or breast-milk jaundice, rather than supporting and improving breastfeeding technique and frequency.^[3][1]
• Discharging a newborn before 72 hours of age without a clear, appropriately timed follow-up bilirubin plan, given that peak bilirubin typically occurs at 72-120 hours — after most families are already home.^[1]
• Using a generic or adult-style threshold instead of the correct gestational-age- and neurotoxicity-risk-factor-specific threshold.^[1]
• Waiting for classic advanced signs of acute bilirubin encephalopathy (seizures, a high-pitched cry, opisthotonus) before escalating, rather than acting on earlier, subtler signs such as lethargy, poor feeding, and hypotonia.^[2]
• Treating universal G6PD screening as a routine newborn test expected to change acute management — results do not return quickly enough; caregiver education about hemolytic triggers is the practical substitute.^[4]
• Assuming a jaundiced infant who looks generally unwell, feeds poorly, or is febrile is simply "more jaundiced" rather than evaluating for a coexisting problem beyond routine jaundice workup.
• Recommending sunlight exposure through a window as a substitute for clinical phototherapy.

How to use this table: Doses are adult doses and require patient-specific confirmation (renal/hepatic function, weight, allergy history). Pediatric dosing is weight-based per the current product monograph unless stated. Drug pricing is intentionally omitted. Select any drug name to open its complete Pharmasist Drug Database page.

Intravenous Immunoglobulin (IVIG) — Isoimmune Hemolytic Disease Only

The only drug with a genuine, guideline-recognized role in routine neonatal hyperbilirubinemia management, and even here it is reserved for a specific scenario: isoimmune (Rh or ABO) hemolytic disease with TSB at or approaching the pre-exchange-transfusion threshold, when exchange transfusion cannot be readily arranged. It is always an adjunct to intensive phototherapy, not a substitute for it, and evidence for benefit is genuinely mixed.

Not Recommended for Routine Neonatal Jaundice

Included here only because a pharmacist may encounter historical prescribing habits or parent questions about these options — neither has a routine, guideline-endorsed role in ordinary neonatal hyperbilirubinemia.